Macrogenics vs Regenxbio
Regenxbio reported revenue of $170 million in fiscal 2025, about the same as Macrogenics' $150 million in fiscal 2025. Macrogenics' revenue fell 0.3% in its latest year, and Regenxbio's grew 104.5%. Macrogenics had an operating margin of -48.7%, against -94.6% at Regenxbio. Free cash flow was −$83 million at Macrogenics and −$126 million at Regenxbio.
Side by side
| Macrogenics | Regenxbio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $150M | $170M |
| Revenue growth | −0.3% | 104.5% |
| Revenue growth a year, last 5 years | 7.3% | 2.0% |
| Gross margin | 100.0% | — |
| Operating margin | −48.7% | −94.6% |
| Net margin | −49.9% | −113.8% |
| Free cash flow | −$83M | −$126M |
| Free cash flow margin | −55.5% | −74.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.8% | 4.2% |
| Last close | $1.98 | $7.18 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $129,086 | bought $949,541, sold $939,970 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MacrogenicsRegenxbio
Operating margin
Percent of revenue
MacrogenicsRegenxbio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MacrogenicsRegenxbio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Macrogenics and Regenxbio pages.